Published in J Infect Dis on March 01, 2005
Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol (2010) 6.18
Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog (2006) 2.26
Tuberculosis: drug resistance, fitness, and strategies for global control. Eur J Pediatr (2007) 1.41
Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation. BMC Med (2013) 1.17
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.09
Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2014) 0.92
Molecular patterns of multidrug resistance of Mycobacterium tuberculosis in Georgia. Int J Mycobacteriol (2013) 0.77
Factors Associated with Missed Detection of Mycobacterium tuberculosis by Automated BACTEC MGIT 960 System. Biomed Res Int (2016) 0.75
Metabolic Compensation of Fitness Costs Is a General Outcome for Antibiotic-Resistant Pseudomonas aeruginosa Mutants Overexpressing Efflux Pumps. MBio (2017) 0.75
Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis (2003) 3.27
Effect of delayed versus early umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised controlled trial. BMJ (2011) 3.27
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother (2002) 2.07
Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72
Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect Dis (2013) 1.62
Impact of physician-related factors on sickness certification in primary health care. Scand J Prim Health Care (2006) 1.54
Criteria for discharge of patients with Ebola virus diseases in high-income countries. Lancet Glob Health (2015) 0.90
Effects of delayed compared with early umbilical cord clamping on maternal postpartum hemorrhage and cord blood gas sampling: a randomized trial. Acta Obstet Gynecol Scand (2012) 0.83
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity. Retrovirology (2012) 0.82
Development and assessment of criteria to select projects for funding in the EU health programme. Eur J Public Health (2011) 0.79
Effects of delayed cord clamping on neurodevelopment and infection at four months of age: a randomised trial. Acta Paediatr (2013) 0.79
Editorial: Tuberculosis research: an end to neglect and negligence. Trop Med Int Health (2004) 0.75